Evaxion Biotech A/S
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Helen Katrina Tayton-Martin
- Full Time Employees
- 46
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Dr. Neergaards Vej Horsholm ND Denmark 2970
- IPO Date
- Feb 5, 2021
- CIK
- 0001828253
- Website
- evaxion.ai
- Similar Companies
- Business
- Evaxion A/S (NASDAQ: EVAX) is a clinical-stage TechBio company that leverages its proprietary AI-Immunology™ platform to discover, design, and develop novel immunotherapies, including personalized cancer vaccines and prophylactic vaccines for infectious diseases. The company's core offerings encompass EVX-01, a personalized cancer immunotherapy in phase 2 for metastatic melanoma and advanced to non-small cell lung cancer in combination with pembrolizumab; EVX-02, a DNA-based cancer vaccine that completed phase 1/2a in adjuvant melanoma; EVX-03, a DNA-based immunotherapy targeting various cancers; EVX-B1 and EVX-B2, prophylactic vaccines against bacterial infections such as Staphylococcus aureus and gonorrhea; EVX-V1, a vaccine candidate for cytomegalovirus (CMV); and emerging programs like EVX-B3 for additional bacterial pathogens and an ERV-based precision cancer vaccine targeting shared tumor antigens, all powered by AI models including PIONEER™ for tumor-specific neoantigens, EDEN™ for infectious disease antigens, and novel predictors for toxins and lead vaccine design. Evaxion targets patients with cancer and high-unmet-need infectious diseases, operating primarily from its headquarters and research facilities in Hørsholm, Denmark, near Copenhagen, with global clinical trials and partnerships. Founded in 2008, Evaxion A/S (formerly Evaxion Biotech A/S until its name change in May 2025) focuses on oncology and infectious disease segments through scalable AI-driven platforms that simulate the human immune system for rapid target identification and immunotherapy development. In recent developments, the company completed patient dosing in the EVX-01 phase 2 trial in January 2025 and reported two-year data in October 2025; entered a transformational partnership with MSD in 2024 covering EVX-B2 and EVX-B3 with $3.2 million upfront, up to $10 million in near-term milestones, and potential $592 million per product in further milestones plus royalties, tracking toward option exercise in late 2025; raised $7.2 million in October 2025 via share sales and warrant exercises to extend cash runway into the second half of 2027; advanced preclinical proof-of-concept for its ERV precision cancer vaccine with a lead candidate expected in late 2025; launched a new toxin antigen predictor and automated vaccine design module to enhance the AI-Immunology™ platform; terminated the EVX-V1 collaboration with ExpreS2ion to retain full rights for potential out-licensing; and opened new headquarters and labs in DTU Science Park, Hørsholm, to support growth. These initiatives underscore Evaxion's multi-partner strategy, pipeline expansion, and platform maturation amid ongoing clinical execution.
Company News
Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript
Evaxion announces business update and second quarter 2026 financial results
Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
Evaxion receives Prix Galien UK Award for Best digital health solution
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript
Evaxion announces business update and first quarter 2026 financial results
Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer
Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
Evaxion concludes Annual General Meeting
Brokerages Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) PT at $11.00
Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress
Notice to convene Evaxion's Annual General Meeting
Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives $11.75 Average Target Price from Analysts